Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Innate Pharma Announces Virtual Key Opinion Leader Event On Lacutamab, A First-In-Class Anti-KIR3DL2 Antibody Currently In Development For Cutaneous T-Cell Lymphoma And Peripheral T Cell Lymphoma

Author: Benzinga Newsdesk | November 27, 2023 02:25am
  • The event will highlight positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome which have been selected for oral presentation at the American Society of Hematology (ASH) Annual Meeting
  • Virtual KOL event will be held on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM CET)

Posted In: IPHA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist